NCT03396900

Brief Summary

rhBMP-2 has the potential to function as a regenerative material in periodontally accelerated osteogenic orthodontics (PAOO). This study aimed to assess the effects of PAOO with BMP-2 on outcomes such as treatment period, bone density, healing and pain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jul 2016

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2016

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 27, 2017

Completed
15 days until next milestone

First Posted

Study publicly available on registry

January 11, 2018

Completed
Last Updated

January 11, 2018

Status Verified

January 1, 2018

Enrollment Period

1.1 years

First QC Date

December 27, 2017

Last Update Submit

January 4, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Orthodontic treatment duration

    Periodic recall of patients for every two weeks was done to assess the amount of crowding relieved by using digital Vernier calipers and photographs. The time taken to unravel the crowding in the pretreatment and post treatment study models and photographs was recorded.

    Up to 6 months

Study Arms (2)

RhBMP-2 Protein, Recombinant

ACTIVE COMPARATOR

15 subjects treated with corticotomy with rhBMP-2 (C+BMP)

Drug: RhBMP-2 Protein, Recombinant

Conventional Corticotomy

EXPERIMENTAL

15 subjects treated with conventional corticotomy (C) as in the PAOO protocol

Other: Conventional Corticotomy

Interventions

Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.

Also known as: Osteogenic protein
RhBMP-2 Protein, Recombinant

A conventional PAOO Surgical procedure will be performed for individuals in this arm

Also known as: PAOO Surgery
Conventional Corticotomy

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • subjects with moderate crowding of lower incisors based upon Little's index and willing to undergo undergoing orthodontic treatment with extraction therapy of lower 1st premolars and PAOO were included in the study.

You may not qualify if:

  • Smokers and subjects with severe crowding of anterior teeth, periodontitis and systemic diseases were excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

SVS Institute of Dental Sciences, Mahabubnagar

Hyderabad, Andhra Pradesh, 509002, India

Location

MeSH Terms

Conditions

Malocclusion

Interventions

recombinant human bone morphogenetic protein-2

Condition Hierarchy (Ancestors)

Tooth DiseasesStomatognathic Diseases

Study Officials

  • Madhukar R Rachala, MDS

    SVS Institute of Dental Sciences

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Masking Details
The orthodontist (HA) who performed the relevant treatment after PAOO was different from the orthodontist (MRR) randomizing the subjects into C or C+BMP groups and hence was blinded to the treatment received by the patient. One periodontist performed the PAOO surgeries (KM) and another periodontist (RVC) blinded to the therapy received by the subjects recorded the clinical and radiographic data pertinent to the study. The blind was not broken until the end of study period.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study is a randomized controlled clinical trial where systemically healthy individuals undergoing orthodontic therapy and willing to participate in the study were referred from the Department of Orthodontics and were followed up over a 6 month period after treatment.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Investigator

Study Record Dates

First Submitted

December 27, 2017

First Posted

January 11, 2018

Study Start

July 1, 2016

Primary Completion

August 1, 2017

Study Completion

November 1, 2017

Last Updated

January 11, 2018

Record last verified: 2018-01

Data Sharing

IPD Sharing
Will not share

Published data will be shared

Locations